Coronary Artery DiseaseNCT00711685
Topical Vancomycin in Prevention of Methicillin-Resistant Staphylococcal Related Mediastinitis in Patients Receiving Coronary Artery Bypass Graft
A study testing coronary artery bypass grafting via midline sternotomy in people with Coronary Artery Disease, run by Far Eastern Memorial Hospital at 1 site in Taiwan.
Trial summary
Sternal or mediastinal infections after heart operation occurs infrequently but carries a high cost in money, morbidity, and mortality. At our hospital, Staphylococcus species cause most of these infections and is uniformly sensitive to vancomycin. Read more about this study
- Who is it for?
- Ages 20 years and older
- Conditions the study is for
- Coronary Artery Disease
- What is being tested?
- coronary artery bypass grafting via midline sternotomy
- Type of treatment
- Surgery or procedure
- How many people
- 50 participants
- Where
- 1 siteTaiwan
- Study dates
- Jan 2007to Dec 2007
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients with coronary artery disease underwent aoronary artery bypass grafting
Who cannot join
- Patients who ever received vancomycin or teicoplanin or linezolids within one week will be excluded. Other exclusion criteria are patients in pregnant, allergic to vancomycin, and hesitate to this study plan.
Trial locations and contacts
1 site in 1 country.
About this study
Sternal or mediastinal infections after heart operation occurs infrequently but carries a high cost in money, morbidity, and mortality. At our hospital, Staphylococcus species cause most of these infections and is uniformly sensitive to vancomycin. However, the relative low concentration of vancomycin in sternal bone was noted given intravenously. Topical vancomycin was therefore considered to apply on the cut edege of sternal bone before closure in patients receiving coronary artery bypass graft to evaluate the effect on reducing the infection rate of staphylococcus related mediastinitis (6). In addition, we try to observe that prophylactic use of topical vancomycin will increase the risk for acquiring resistant pathogen such as VISA (vancomycin-intermediate S. aureus), VRSA (Vancomycin-resistant S. aureus), VRE (vancomycin-resistant enterococcus)
Read the detailed description
Background Postoperative sterno-mediastinitis is a life-threatening complication. Although the incidence rate is about 0.75 to 1.4% in all open heart operations, the association with morbidity, mortality and cost is unacceptably high (1, 2). Some risk factors should be minimized as possible, such as preoperative days in the hospital, and poor controlled blood sugar and other chronic underlying conditions. In addition, patients should shower the night and morning before surgery with chlorhexadine and remove hair with clipper or depilatory crème instead of a shave. These basic rules of sterile technique can't be emphasized enough and may reduce the occurrence of postoperative sterno-mediastinitis form 7.5 to 0.8% (3, 4).
The matter of prophylactic antibiotics is controversial. Although everybody agrees the necessity of using prophylactic antibiotics but which to use and how long it should be administered remain a debate. The most commonly occurring bacterial offenders in the institution always should be considered in selecting of prophylactic antibiotics.
Staphylococcus spp. is most common pathogens in most institutions and also in our hospitals. It is currently recommended that the use of vancomycin for perioperative prophylaxis should be considered only in patients with a life-threatening allergy toβ-lactam antibiotics or at institutions with a high rate of infections caused by MRSA or methicillin-resistant S. epidermidis (5). However, the relative low concentration of vancomycin in sternal bone was noted when given intravenously (5). According to the study performed by Vander et al. in 1989, we also try to apply vancomycin over the cut sternal edges in patients receiving CABG (coronary artery bypassing graft) and to evaluate the effect on reducing the infection of staphylococcus related mediastinitis (6). In addition, we try to observe that prophylactic use of topical vancomycin will increase the risk for acquiring resistant pathogen such as VISA (vancomycin-intermediate S. aureus), VRSA (Vancomycin-resistant S. aureus), VRE (vancomycin-resistant enterococcus).
Aim We try to apply vancomycin over the cut sternal edges in patients receiving CABG (coronary artery bypassing graft) and to evaluate the effect on reducing the infection of staphylococcus related mediastinitis. In addition, we try to observe the use of topical vancomycin will induce the collateral effect on increasing the infections of resistant pathogen such as VISA (vancomycin-intermediate S. aureus), VRSA (Vancomycin-resistant S. aureus), VRE (vancomycin-resistant enterococcus) or other infections caused by GNB or yeast.
Materials and methods
Patients Patients who aged over 20 and receive CABG in our hospital, a 1000-beds medical center, from June 1, 2007 to Dec 31, 2007 will be included in our study. Patients who ever received vancomycin or teicoplanin or linezolids within one week will be excluded. Other exclusion criteria are patients in pregnant, allergic to vancomycin, and hesitate to this study plan. A register of inclusions will be established to avoid inclusion of the same patient twice.
Data collection
Preoperation A standard case report form was designed to collect patents' demographic data, laboratory data and medical conditions. The demographic data include age, gender, hospital unit (ward or ICU) before operation, and the TISS score if patients reside in ICU. The medical conditions include BMI (body mass index), smoking, medical disease, steroid or other immunosuppressants usage, left ventricular ejection fraction, cardiac index, prior hospital staying days, previous cardiac surgical procedure, previous radiotherapy over operation site, other infection diseases with antibiotics usage, catheters in place. Laboratory data including WBC, platelet counts, hemoglobulin, BUN, Cr, albumin and aminotransferase are recorded.
Operation During operation, ASA score (American Society of Anethesiologists risk score), main operators should be recorded before operation. In addition, overall operation time, which vessels be harvested if extracorporeal bypass used and the used time, if IABP (intraaortic balloon pumping), ECMO (extracorporeal membrane oxygenation), external pacemaker used during operation will be recorded.
Postoperation After operation, the units of blood product transfusion, catheter in placed, wound condition will be recorded. The condition of wound should be evaluated and be recorded everyday until postoperative 30th days. The thoracic wound condition was stratified into three grades: "0" = clean wound, "1"= local swelling, redness or heat and tenderness, "2" = purulent discharge. In addition, serum Vancomycin level will be checked everyday for one week in study group. The date and pathogens of concomitant infections, such as ventilator-associated pneumonia, catheter-related infection, urinary tract infection, donor site wound infection will be also recorded if develop. Once methicillin-resistant staphylococcal species yield, MIC (minimal inhibit concentration) of vancomycin and molecular typing of this pathogen will be performed.
Furthermore, the complications of sternal wound infection, including acute renal failure with or without long term hemodialysis, ARDS (acute respiratory distress syndrome), septic shock, disseminated intravascular coagulopathy, heptic dysfunction and mortality will be also recorded. The overall hospitalization days will also be recorded.
Pre - and Intra-operative preparation protocol Nasal swab and anal swab should be performed in all patients. All patients should shower the night and morning before surgery with chlorhexadine. Hair removal should be used clipper or depilatory crème instead of a shave just before operation. Prophylactic antibiotics with cefazolin 1g should be administered intravenous 30 minutes before operation, and one extra dose of 1g cefazolin will be administered if operation time over 2 hours. The gloves and instruments used to harvest saphenous vein will be changed before working in intrathoracic field. Before the sternum been closed, a hemostatic paste containing 1gm of powdered absorbable gelatin (Gelfoam, Upjohn Co., Kalamazoo, Mich.) and topical thrombin (1000 units/ml) (Armour Pharmaceutical Co., Kankakee, Ill.) will be applied to the cut edges of the sternum. Vancomycin mixture is prepared by 500mg of powdered vancomycin (Vancocin; Eli Lilly \& Co.) been added to above mixture before application. Patients with odd-numbered medical record will be applied with vancomycin mixture. In either cases, the resultant material was made by adding sufficient thrombin to achieve a consistency some what like that of fresh pie dough (5).
Study endpoints Primary endpoint is to compare the infection rate of methicillin-resistant staphylococcal pathogen between the group of prophylactic systemic cefazolin used only and the group of topical vancomycin added.
Secondary endpoints are, first, to identify the associated risk factors and the consequent complications of sternal wound infections and then compare the cost-effective in these two groups. Secondary, we compare the pathogens, either inducing infection or colonization, between these two groups.
Definitions Surgical site infection is defined according to the CDC's suggestion (6). Patients with an intravascular device-related infection was defined as (1) at least one positive blood culture obtained from a peripheral vein, clinical manifestations of infections (i.e., fever, chills, and/or hypotension), and no apparent source for the bacteremia except catheter or (2) one positive semi-quantitative (>15 CFU/catheter segment) whereby the same organism (species and antibiogram) is isolated form the catheter segment and peripheral blood (6). Ventilator associated pneumonia is defined Patients had new or progressive pulmonary infiltrates 48 hours after endotracheal intubation plus 1 of the following: positive blood culture results, radiographic evidence of cavitation, or histologic evidence of pneumonia, or 2 or more of the following: new fever, new leukocytosis, or grossly purulent tracheal aspirates (7).
Statistical analysis For the analysis, means and standard deviation (SD) were calculated as summaries of continuous variables. The comparison was performed with Mann-Whitney U method for continuous variables, and with Chi-square test, Fisher's exact tests, or ANOVA for categorical variables. Factors associated with death in univariate analysis (p<0.1) were further evaluated with multivariate analysis. Data were collected in a Microsoft Excel database (Microsoft Excel 2001; Microsoft Corporation, Seattle, WA) and analyzed with SPSS software for Window (Release 10.0; SPSS, Inc., Chicago, IL).
- Conditions
- Coronary Artery Disease
- Being tested
- coronary artery bypass grafting via midline sternotomy
- Keywords
- Topical vancomycin, mediastinitis, coronary, artery, bypass, graft, Patients
- Medical subject headings
- Coronary Artery Disease, Mediastinitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
coronary artery bypass grafting via midline sternotomyProcedure or surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jul 2008 (estimated)
- Study startJan 2007
- Primary completionDec 2007
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Coronary Artery DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Far Eastern Memorial Hospital
- Sponsor type
- University, hospital or other
- Investigators
- Kuan-Ming Chiu, M.D., Study director, Far Eastern Memorial Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00711685
- Sponsor's protocol ID
- 95033
- Other IDs
- FEMH-95-C-040
- Status last verified
- Jul 2008
- First submitted
- 7 Jul 2008
- Last updated
- 9 Jul 2008
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 9 Jul 2008. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Topical Vancomycin in Prevention of Methicillin-Resistant Staphylococcal Related Mediastinitis in Patients Receiving Coronary Artery Bypass Graft
- ClinicalTrials.gov ID
- NCT00711685
- Acronym / sponsor ID
- 95033
- Conditions
- Coronary Artery Disease
- Keywords
- Topical vancomycin, mediastinitis, coronary, artery, bypass, graft, Patients
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Far Eastern Memorial HospitalUniversity, hospital or other
- Study start
- Jan 2007
- Primary completion
- Dec 2007 (actual)
- First posted
- 9 Jul 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Sternal or mediastinal infections after heart operation occurs infrequently but carries a high cost in money, morbidity, and mortality. At our hospital, Staphylococcus species cause most of these infections and is uniformly sensitive to vancomycin. However, the relative low concentration of vancomycin in sternal bone was noted given intravenously. Topical vancomycin was therefore considered to apply on the cut edege of sternal bone before closure in patients receiving coronary artery bypass graft to evaluate the effect on reducing the infection rate of staphylococcus related mediastinitis (6). In addition, we try to observe that prophylactic use of topical vancomycin will increase the risk for acquiring resistant pathogen such as VISA (vancomycin-intermediate S. aureus), VRSA (Vancomycin-resistant S. aureus), VRE (vancomycin-resistant enterococcus)
Detailed description
Background Postoperative sterno-mediastinitis is a life-threatening complication. Although the incidence rate is about 0.75 to 1.4% in all open heart operations, the association with morbidity, mortality and cost is unacceptably high (1, 2). Some risk factors should be minimized as possible, such as preoperative days in the hospital, and poor controlled blood sugar and other chronic underlying conditions. In addition, patients should shower the night and morning before surgery with chlorhexadine and remove hair with clipper or depilatory crème instead of a shave. These basic rules of sterile technique can't be emphasized enough and may reduce the occurrence of postoperative sterno-mediastinitis form 7.5 to 0.8% (3, 4).
The matter of prophylactic antibiotics is controversial. Although everybody agrees the necessity of using prophylactic antibiotics but which to use and how long it should be administered remain a debate. The most commonly occurring bacterial offenders in the institution always should be considered in selecting of prophylactic antibiotics.
Staphylococcus spp. is most common pathogens in most institutions and also in our hospitals. It is currently recommended that the use of vancomycin for perioperative prophylaxis should be considered only in patients with a life-threatening allergy toβ-lactam antibiotics or at institutions with a high rate of infections caused by MRSA or methicillin-resistant S. epidermidis (5). However, the relative low concentration of vancomycin in sternal bone was noted when given intravenously (5). According to the study performed by Vander et al. in 1989, we also try to apply vancomycin over the cut sternal edges in patients receiving CABG (coronary artery bypassing graft) and to evaluate the effect on reducing the infection of staphylococcus related mediastinitis (6). In addition, we try to observe that prophylactic use of topical vancomycin will increase the risk for acquiring resistant pathogen such as VISA (vancomycin-intermediate S. aureus), VRSA (Vancomycin-resistant S. aureus), VRE (vancomycin-resistant enterococcus).
Aim We try to apply vancomycin over the cut sternal edges in patients receiving CABG (coronary artery bypassing graft) and to evaluate the effect on reducing the infection of staphylococcus related mediastinitis. In addition, we try to observe the use of topical vancomycin will induce the collateral effect on increasing the infections of resistant pathogen such as VISA (vancomycin-intermediate S. aureus), VRSA (Vancomycin-resistant S. aureus), VRE (vancomycin-resistant enterococcus) or other infections caused by GNB or yeast.
Materials and methods
Patients Patients who aged over 20 and receive CABG in our hospital, a 1000-beds medical center, from June 1, 2007 to Dec 31, 2007 will be included in our study. Patients who ever received vancomycin or teicoplanin or linezolids within one week will be excluded. Other exclusion criteria are patients in pregnant, allergic to vancomycin, and hesitate to this study plan. A register of inclusions will be established to avoid inclusion of the same patient twice.
Data collection
Preoperation A standard case report form was designed to collect patents' demographic data, laboratory data and medical conditions. The demographic data include age, gender, hospital unit (ward or ICU) before operation, and the TISS score if patients reside in ICU. The medical conditions include BMI (body mass index), smoking, medical disease, steroid or other immunosuppressants usage, left ventricular ejection fraction, cardiac index, prior hospital staying days, previous cardiac surgical procedure, previous radiotherapy over operation site, other infection diseases with antibiotics usage, catheters in place. Laboratory data including WBC, platelet counts, hemoglobulin, BUN, Cr, albumin and aminotransferase are recorded.
Operation During operation, ASA score (American Society of Anethesiologists risk score), main operators should be recorded before operation. In addition, overall operation time, which vessels be harvested if extracorporeal bypass used and the used time, if IABP (intraaortic balloon pumping), ECMO (extracorporeal membrane oxygenation), external pacemaker used during operation will be recorded.
Postoperation After operation, the units of blood product transfusion, catheter in placed, wound condition will be recorded. The condition of wound should be evaluated and be recorded everyday until postoperative 30th days. The thoracic wound condition was stratified into three grades: "0" = clean wound, "1"= local swelling, redness or heat and tenderness, "2" = purulent discharge. In addition, serum Vancomycin level will be checked everyday for one week in study group. The date and pathogens of concomitant infections, such as ventilator-associated pneumonia, catheter-related infection, urinary tract infection, donor site wound infection will be also recorded if develop. Once methicillin-resistant staphylococcal species yield, MIC (minimal inhibit concentration) of vancomycin and molecular typing of this pathogen will be performed.
Furthermore, the complications of sternal wound infection, including acute renal failure with or without long term hemodialysis, ARDS (acute respiratory distress syndrome), septic shock, disseminated intravascular coagulopathy, heptic dysfunction and mortality will be also recorded. The overall hospitalization days will also be recorded.
Pre - and Intra-operative preparation protocol Nasal swab and anal swab should be performed in all patients. All patients should shower the night and morning before surgery with chlorhexadine. Hair removal should be used clipper or depilatory crème instead of a shave just before operation. Prophylactic antibiotics with cefazolin 1g should be administered intravenous 30 minutes before operation, and one extra dose of 1g cefazolin will be administered if operation time over 2 hours. The gloves and instruments used to harvest saphenous vein will be changed before working in intrathoracic field. Before the sternum been closed, a hemostatic paste containing 1gm of powdered absorbable gelatin (Gelfoam, Upjohn Co., Kalamazoo, Mich.) and topical thrombin (1000 units/ml) (Armour Pharmaceutical Co., Kankakee, Ill.) will be applied to the cut edges of the sternum. Vancomycin mixture is prepared by 500mg of powdered vancomycin (Vancocin; Eli Lilly \& Co.) been added to above mixture before application. Patients with odd-numbered medical record will be applied with vancomycin mixture. In either cases, the resultant material was made by adding sufficient thrombin to achieve a consistency some what like that of fresh pie dough (5).
Study endpoints Primary endpoint is to compare the infection rate of methicillin-resistant staphylococcal pathogen between the group of prophylactic systemic cefazolin used only and the group of topical vancomycin added.
Secondary endpoints are, first, to identify the associated risk factors and the consequent complications of sternal wound infections and then compare the cost-effective in these two groups. Secondary, we compare the pathogens, either inducing infection or colonization, between these two groups.
Definitions Surgical site infection is defined according to the CDC's suggestion (6). Patients with an intravascular device-related infection was defined as (1) at least one positive blood culture obtained from a peripheral vein, clinical manifestations of infections (i.e., fever, chills, and/or hypotension), and no apparent source for the bacteremia except catheter or (2) one positive semi-quantitative (>15 CFU/catheter segment) whereby the same organism (species and antibiogram) is isolated form the catheter segment and peripheral blood (6). Ventilator associated pneumonia is defined Patients had new or progressive pulmonary infiltrates 48 hours after endotracheal intubation plus 1 of the following: positive blood culture results, radiographic evidence of cavitation, or histologic evidence of pneumonia, or 2 or more of the following: new fever, new leukocytosis, or grossly purulent tracheal aspirates (7).
Statistical analysis For the analysis, means and standard deviation (SD) were calculated as summaries of continuous variables. The comparison was performed with Mann-Whitney U method for continuous variables, and with Chi-square test, Fisher's exact tests, or ANOVA for categorical variables. Factors associated with death in univariate analysis (p<0.1) were further evaluated with multivariate analysis. Data were collected in a Microsoft Excel database (Microsoft Excel 2001; Microsoft Corporation, Seattle, WA) and analyzed with SPSS software for Window (Release 10.0; SPSS, Inc., Chicago, IL).
Study design
- Primary purpose
- Prevention
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
Who may qualify
- Ages
- 20 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Patients with coronary artery disease underwent aoronary artery bypass grafting
Key exclusion criteria (1 listed)
- Patients who ever received vancomycin or teicoplanin or linezolids within one week will be excluded. Other exclusion criteria are patients in pregnant, allergic to vancomycin, and hesitate to this study plan.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| coronary artery bypass grafting via midline sternotomy | Procedure or surgery | – |
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jul 2008.
Related trials for Coronary Artery Disease
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
Active, not recruiting
Shockwave™ vs Surgical Endarterectomy for Calcified Severe Common Femoral Artery Stenosis: Comparison of Efficacy, Safety and Long-Term Outcomes
Common Femoral Artery Stenosis, Calcification; Heart
Not yet recruitingPhase 4
Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
Coronary Artery Disease, Coronary Artery Bypass Grafting
RecruitingObservational study
Preoperative Gastric Ultrasound and Left Ventricular Function in Coronary Artery Bypass Surgery
Coronary Artery Disease, Left Ventricular Systolic Dysfunction
Active, not recruiting
The OCTOBER Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction (OCTOBER)
Ischaemic Heart Disease, Ischemic Heart Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Kuan-Ming Chiu, M.D. study director
Far Eastern Memorial Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing coronary artery bypass grafting via midline sternotomy in people with Coronary Artery Disease, run by Far Eastern Memorial Hospital at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Jul 2008. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jul 2008.